Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring
| Autor: | Julio Pascual, Sergi Pascual, Higini Cao, E. Padilla, María José Pérez-Sáez, Montserrat Folgueiras, Antoni Barrilado-Jackson, Laura Ribera, Dolores Redondo-Pachón, Marta Crespo, Jorge Eguía, Eulàlia Solà-Porta, S Hurtado, Anna Faura, Laura Río-No, Daniel Echeverria-Esnal, Francesc Barbosa |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
COVID-19 Vaccines
infectious disease medicine.medical_treatment Interferon gamma release assay kidney transplantation/nephrology Antibodies Viral clinical research/practice Peritoneal dialysis T cell biology Immune system Renal Dialysis COVID‐19 vaccine medicine Humans Immunology and Allergy Pharmacology (medical) RNA Messenger immunobiology Dialysis Transplantation biology SARS-CoV-2 business.industry ELISPOT Immunogenicity Immunity COVID-19 Original Articles Allografts Kidney Transplantation Immunology biology.protein dialysis Original Article Hemodialysis Antibody business antibody biology Interferon-gamma Release Tests |
| Zdroj: | American Journal of Transplantation |
| ISSN: | 1600-6135 |
| DOI: | 10.1111/ajt.16854 |
| Popis: | Studies are urgently needed to characterize immunogenicity, efficacy, and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in kidney transplant (KT) recipients, excluded from major clinical trials. Complex ELISPOT and other cellular response techniques have been applied, but simpler tools are needed. An easy-to-use real-world monitoring of SARS-CoV-2 IgG antibodies against the Spike protein and QuantiFERON® SARS-CoV-2 IFNI³ release assay (IGRA) were performed at baseline and 28 days after the second dose in KT recipients and controls (dialysis patients and healthy ones). All healthy controls and >95% dialysis controls became positive for anti-S IgG antibodies, while only 63.3% of KT patients seroconverted with a very low antibody level. A positive IGRA was documented in 96.9% of controls, 89.3% peritoneal dialysis, 77.6% hemodialysis, 61.3% of KT patients transplanted more than 1 year ago and only 36% of those transplanted within the previous 12 months. Overall, 100% of healthy controls, 95.4% of dialysis patients and 78.8% KT recipients developed any immune response (humoral and/or cellular) against SARS-CoV-2. KT patients showed low rates of immune responses to mRNA Coronavirus infectious disease 2019 vaccines, especially those with recent transplantations. Simple humoral and cellular monitoring is advisable, so that repeated doses may be scheduled according to the results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text